Strides Pharma Peer Comparison

NSE: STAR | BSE: 532531

₹1,104.90

₹71.80 (6.95%)

As on 27-Oct-2026 12:44IST

Market cap

₹9,853 Cr

Revenue (TTM)

₹5,004 Cr

P/E Ratio

16.1

P/B Ratio

Div. Yield

0.5 %

Edit

	Strides Pharma	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Market cap (₹ Cr)	9,853	17,627	17,861	16,870	16,443
Revenue (₹ Cr)	5,004	2,287	1,682	2,570	3,330
Net Profit (₹ Cr)	635.34	678.07	273.51	735.15	720.77
Net Margin (%)	12.33	28.10	16.19	26.88	21.60
RoE (%)	19.77	19.73	11.15	19.16	18.93
Price to Earnings	16.06	26.49	60.07	22.95	23.24
Price-To-Book	3.01	4.80	6.65	3.83	3.97

Income Statement (₹ Cr)

	Strides Pharma	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Operating Revenue	5,004.35	2,287.33	1,682.47	2,569.77	3,329.63
Total Income	5,151.37	2,413.29	1,689.83	2,735.39	3,337.47
Total Expenditure	4,067.36	1,490.75	1,203.91	1,628.14	2,168.88
EBITDA	936.99	796.58	478.55	941.63	1,160.75
Depreciation	209.91	78.10	126.01	57.58	285.40
EBIT	727.08	718.48	352.55	884.05	875.35
Interest	171.65	0.88	52.11	7.69	187.51
Other Income	147.02	125.96	7.37	165.62	7.84
Exceptional Items	44.72	0.00	12.16	-49.16	-53.14
Profit before Tax	747.17	843.56	319.96	992.82	642.54
Provision for Tax	111.84	165.49	46.45	257.67	-78.23
Profit after Tax	635.34	678.07	273.51	735.15	720.77

	Strides Pharma	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Shareholder's Funds	3,107.57	3,586.42	2,591.20	4,202.90	4,144.34
Minority Interest	-20.92	-12.71	0.00	0.00	-10.85
Non-Current Liabilities	882.40	28.74	266.35	91.50	758.48
Current Liabilities	2,895.49	385.94	848.06	627.48	2,681.14
Total Liabilities	6,806.56	4,037.51	3,705.61	4,921.88	7,246.72

	Strides Pharma	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Non-Current Assets	3,044.86	1,291.22	2,525.44	770.28	5,578.78
Current Assets	3,612.79	2,585.66	1,109.77	3,803.22	1,800.86
Total Assets	6,806.56	4,037.51	3,705.61	4,921.88	7,246.72
Total Debt*	1,668.69	0.57	657.97	2.50	2,309.68
Net Current Assets	717.30	2,199.72	261.71	3,175.74	-880.28
Contingent Liabilities	118.51	17.53	160.01	370.49	51.57

	Strides Pharma	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Cash From Operating Activities	702.52	523.24	342.18	967.57	537.99
Cash Flow from Investing Activities	-173.04	-582.30	-325.92	-561.67	-369.46
Cash from Financing Activities	-453.41	-46.46	13.62	-798.31	-313.53
Net Cash Inflow / Outflow	76.07	-105.52	29.88	-392.41	-145.00

	Strides Pharma	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
ROCE (%)	18.57	24.97	11.43	23.39	14.47
ROE (%)	19.77	19.73	11.15	19.16	18.93
ROA (%)	9.79	18.69	7.80	14.95	9.78
EBIT Margin (%)	14.53	31.41	20.95	34.40	26.29
Net Margin (%)	12.33	28.10	16.19	26.88	21.60
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Strides Pharma	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Revenue Growth (%)	8.07	15.01	27.91	10.69	11.06
EBIT Growth (%)	14.28	18.45	58.32	24.14	13.71
Net Profit Growth (%)	81.52	19.61	149.56	-9.09	60.98
EPS Growth (%)	54.35	17.73	-3.57	14.40	80.38
Book Value Growth (%)	21.78	26.75	9.67	-0.34	36.71

	Strides Pharma	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Price / Earnings	16.40	25.95	62.86	21.88	20.06
Price / Book Value	2.90	4.70	6.56	3.83	3.80
Dividend Yield (%)	0.48	0.35	0.07	2.03	0.00
EV/EBITDA	11.70	20.41	38.10	14.62	15.14
Market Cap (₹ Cr)	8,643.60	11,439.22	6,819.66	21,592.90	17,980.08

	Strides Pharma	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Debt to Equity	0.18	0.00	0.07	0.00	0.10
Short term debt to equity ratio	0.33	0.00	0.16	0.00	0.12
Current Ratio	1.25	6.70	1.31	6.06	0.67
Quick Ratio	0.68	5.59	0.88	5.31	0.49
Interest Coverage	5.35	959.59	7.14	130.11	4.43

	Strides Pharma	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Debtors to sales (%)	25.76	36.10	30.84	7.07	18.98
Asset Turnover	0.77	0.63	0.48	0.52	0.45
Receivable days	64.34	121.68	113.81	26.06	63.88
Inventory Days	75.20	63.83	84.76	65.95	43.27
Payable days	218.23	108.28	101.94	81.01	151.85
Cash Conversion Cycle	-78.69	77.23	96.62	11.00	-44.70

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.